RxDoctor Payments Data

David Friedman

Nephrology · Boston, MANPI 1194763482

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $19,750,000 of the $19,786,647 with a category attached, or 99.8%. Vertex accounts for 100.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $18,755,428 and has fallen 100.0% since, to $3,704 in 2025. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,786,647in general payments, 2019–2025

Across 35 payments — averaging $565,333 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$19.8M
  • Sanofi$7K
  • Genentech USA, Inc.$61
$4,673,381in research payments, 2019–2025

Across 6 payments — averaging $778,897 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$4.7M

What the payments were for

  • Royalty or licence$19,750,000100%
  • Consulting fees$35,6790%
  • Travel & lodging$6060%
  • Food & beverage$3620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex29$19,779,451
Sanofi5$7,134
Genentech USA, Inc.1$61

How this compares

$19,786,647 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Other nephrology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →